SecBot SecBot
8-K ·Filed Aug 13, 2026

TIL

Instil Bio, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed3mo ago SEC0001789769-26-000055
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor for any definitive agreement on an acquisition or in-licensing transaction, which would be the primary catalyst for this stock. Absent a deal, the stock is likely to trade on cash runway and general biotech sentiment, no near-term operational catalyst exists.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.38
T+0 close · Aug 13, 2026 · via day close
Latest settled
−12.33%
T+60 · $6.47
Vs SPY
−9.28%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 14 $7.38entry
  2. T+1 · 3mo ago −0.27%α +0.20% · $7.36
  3. T+5 · 3mo ago +2.71%α +4.08% · $7.58
  4. T+20 · 2mo ago +0.95%α +2.94% · $7.45
  5. T+60 · 8d ago −12.33%α −9.28% · $6.47
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Instil Bio reported Q2 2026 results with a GAAP net loss of $0.63 per share, narrowing from a $3.24 loss in Q2 2025, driven by sharply lower operating expenses as the company maintains a lean cash-burn structure while evaluating acquisition and in-licensing opportunities. Cash and marketable securities stood at $69.9M, down from $76.3M at year-end 2025, but management expects this to fund operations beyond 2027. The filing is routine for a pre-revenue biotech with no pipeline catalysts, the stock's direction hinges entirely on whether a transaction materializes, not on the quarterly loss trajectory.

Key Financial Metrics

EPS
−$0.63
Rating
in line

Key Facts

  • GAAP net loss per share was $0.63 for Q2 2026, vs $3.24 in Q2 2025
  • Cash, cash equivalents, restricted cash and marketable securities totaled $69.9M as of June 30, 2026
  • Cash runway expected to fund operating plan beyond 2027
  • R&D expenses fell to $0.3M in Q2 2026 from $6.7M in Q2 2025
  • G&A expenses fell to $5.1M in Q2 2026 from $6.2M in Q2 2025
  • No in-process R&D expenses in Q2 2026 vs $10.0M in Q2 2025
  • Company is evaluating potential acquisitions, in-licensing and related opportunities
  • No revenue reported; company is pre-revenue

Financial Impact

Net loss of $4.3M in Q2 2026 vs $21.4M in Q2 2025; cash burn of ~$6.4M in H1 2026

net losscash positionoperating expenses

Risk Factors

  • No pipeline assets or revenue-generating operations, company is a cash shell seeking a transaction
  • Cash burn continues at ~$3-4M per quarter, reducing the acquisition currency over time
  • No guarantee that a suitable acquisition or in-licensing opportunity will be identified or consummated

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
71% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001789769-26-000055
Document: til-20260813.htm0001789769-26-000055
Document: 0001789769-26-000055-index-headers.html0001789769-26-000055
Document: 0001789769-26-000055-index.html0001789769-26-000055
Document: 0001789769-26-000055.txt0001789769-26-000055
8-K Data (Synthetic)0001789769-26-000055

Track record

8 reports on TIL

Performance horizon
Filters
  1. Nov 16, 2026today 8-K Neutral 4/10 Entry $6.22 Now $5.75 −7.56% settles Dec 15
  2. Aug 13, 202613w ago Press Release Neutral 4/10 No price data
  3. Aug 13, 202613w ago 8-K Neutral 4/10 Viewing Entry $7.38 to $7.45 Now $5.75 −22.09% ▲ +0.95% +2.94% vs SPY
  4. May 15, 202626w ago 8-K Neutral 4/10 No price data
  5. May 15, 202626w ago Press Release Neutral 4/10 Entry $8.07 to $7.92 Now $5.75 −28.75% ▼ −1.86% −3.98% vs SPY
  6. Apr 24, 202629w ago DEFA14A Neutral 2/10 Entry $8.13 to $8.12 Now $5.75 −29.27% ▼ −0.12% −5.08% vs SPY
  7. Apr 3, 202632w ago 8-K Neutral 4/10 Entry $8.46 to $7.84 Now $5.75 −32.03% ▼ −7.33% −16.31% vs SPY
  8. Mar 27, 202633w ago Press Release Mixed 5/10 Entry $7.79 to $8.13 Now $5.75 −26.19% ▲ +4.36% −8.38% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 13, 2026